At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Ferric Carboxymaltose (FCM) +1 moredrug
Likely dose
Ferric Carboxymaltose (FCM) 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravenous Iron Metabolism in Restless Legs Syndrome
In Brief
A Phase 2 clinical trial evaluating Ferric Carboxymaltose (FCM) and Placebo for Restless Legs. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedMay 2008
Primary CompletionDec 2010
Study CompletionDec 2012
TodayJul 2026
First PostedMay 28, 2008
Enrollment StartNov 1, 2006
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 18.1 years ago
Interventions
Ferric Carboxymaltose (FCM)drug
500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
Placebodrug
250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4